Cargando…
Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot
BACKGROUND: Controversy exists for the use of Ki67 protein expression as a predictive marker to select patients who do or do not derive benefit from adjuvant endocrine therapy. Whether other proliferation markers, like Cyclin D1, and mitotic count can also be used to identify those estrogen receptor...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057037/ https://www.ncbi.nlm.nih.gov/pubmed/30041599 http://dx.doi.org/10.1186/s12885-018-4516-1 |